Pathophysiology and Clinical Consequences of Atrial Fibrillation in Hypertrophic Cardiomyopathy

Diagnosis and Management of Hypertrophic Cardiomyopathy

Volumn , Issue , 2007, Pages 105-120

  Olivotto, Iacopo ^a   Maron, Barry J ^b,c   Cecchi, Franco ^a  

^a CAREGGI UNIVERSITY HOSPITAL   (Italy)

^b MINNEAPOLIS HEART INSTITUTE FOUNDATION   (United States)

^c TUFTS MEDICAL CENTER   (United States)

Author keywords

Arrhythmia; Atrial fibrillation; Atrial systole; Left atrial dilatation; Morphological

Indexed keywords

EID: 70249148823     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470987469.ch6     Document Type: Chapter

References (80)

1. Maron BJ. Hypertrophic cardiomyopathy. Lancet 1997; 350: 127-33.
2. Spirito P, Seidman CE, McKenna WJ, Maron BJ. The management of hypertrophic cardio-myopathy. N Engl J Med 1997; 336: 775-85.
3. Wigle ED, Rakowski H, Kimball BP, Williams WG. Hypertrophic cardiomyopathy. Clinical spectrum and treatment. Circulation 1995; 92: 1680-92.
4. Olivotto I, Cecchi F, Casey SA, Dolara A, Traverse JH, Maron BJ. Impact of atrial fibrillation on the clinical course of hypertrophic cardiomyopathy. Circulation 2001; 104: 2517-24.
5. Cecchi F, Olivotto I, Montereggi A, Santoro G, Dolara A, Maron BJ. Hypertrophic cardio-myopathy in Tuscany: Clinical course and outcome in an unselected population. J Am Coll Cardiol 1995; 26: 1529-36.
6. Maron BJ, Casey SA, Poliac L, Gohman TE, Almquist AK, Aeppli DM. Clinical course of hypertrophic cardiomyopathy in a regional United States cohort. JAMA 1999; 281: 650-5.
7. Cecchi F, Montereggi A, Olivotto I, Marconi P, Dolara A, Maron BJ. Risk for atrial fibrilla-tion in patients with hypertrophic cardiomyopathy assessed by signal-averaged P-wave. Heart 1997; 78: 44-9.
8. Maron BJ, Olivotto I, Spirito P et al. Epidemiology of hypertrophic cardiomyopathy-related death: Revisited in a large non-referral based patient population. Circulation 2000; 102: 858-64.
9. Olivotto I, Maron BJ, Cecchi F. Clinical significance of atrial fibrillation in hypertrophic cardiomyopathy. Curr Cardiol Rep 2001; 3: 141-6
10. McKenna WJ. Arrhythmia and prognosis in hypertrophic cardiomyopathy. Eur Heart J 1983; 4 (Suppl. F): 225-34.
11. Savage DD, Seides SF, Maron BJ, Myers DJ, Epstein SE. Prevalence of arrhythmias during 24-hour electrocardiographic monitoring and exercise testing in patients with obstructive and nonobstructive hypertrophic cardiomyopathy. Circulation 1979; 59: 866-75.
12. McKenna WJ, England D, Doi YL, Deanfield JE, Oakley C, Goodwin JF. Arrhythmia in hypertrophic cardiomyopathy: I - Influence on prognosis. Br Heart J 1981; 46: 168-72.
13. Glancy DL, O'Brien KP, Gold HK, Epstein SE. Atrial fibrillation in patients with idiopathic hypertrophic subaortic stenosis. Br Heart J 1970; 32: 652-9.
14. Robinson KC, Frenneaux MP, Stockins B, Karatasakis G, Poloniecki JD, McKenna WJ. Atrial fibrillation in hypertrophic cardiomyopathy: A longitudinal study. J Am Coll Cardiol 1990; 15: 1279-85.
15. Greenspan AM. Hypertrophic cardiomyopathy and atrial fibrillation: A change of per-spective. J Am Coll Cardiol 1990; 15: 1286-7.
16. Ommen SR, Thomson HL, Nishimura RA, Tajik AJ, Schaff HV, Danielson GK. Clinical predictors and consequences of atrial fibrillation after surgical myectomy for obstructive hypertrophic cardiomyopathy. Am J Cardiol 2002; 89: 242-4.
17. Furlan AJ, Craciun AR, Raju NR, Hart N. Cerebrovascular complications associated with idiopathic hypertrophic subaortic stenosis. Stroke 1984; 15: 282-4.
18. Di Pasquale G, Andreoli A, Lusa AM et al. Cerebral embolic risk in hypertrophic car-diomyopathy. In: Baroldi G, Camerini F, Goodwin J, eds. Advances in Cardiomyopathies. Milan: Springer Verlag, 1990: 91-6.
19. Maron BJ, Olivotto I, Bellone P et al. Clinical profile of stroke in 900 patients with hyper-trophic cardiomyopathy. J Am Coll Cardiol 2002; 39: 301-7.
20. Higashikawa M, Nakamuri Y, Yoshida M, Kinoshita M. Incidence of ischemic strokes in hypertrophic cardiomyopathy is markedly increased if complicated by atrial fibrillation. Jpn Circ J 1997; 61: 673-81.
21. Shigematsu Y, Hamada M, Mukai M, Matsuoka H, Sumimoto T, Hiwada K. Mechanism of atrial fibrillation and increased incidence of thromboembolism in patients with hypertrophic cardiomyopathy. Jpn Circ J 1995; 59: 329-36.
22. Kogure S, Yamamoto Y, Yomono S, Hasegawa A, Suzaki T, Murata K. High risk of systemic embolism in hypertrophic cardiomyopathy. Jpn Heart J 1986; 27: 475-80.
23. Doi Y, Kitaoka H. Hypertrophic cardiomyopathy in the elderly: Significance of atrial fibrillation. J Cardiol 2001; 37. 133-8.
24. Brembilla-Perrot B, Terrier de La Chaise A, Beurrier D. Paroxysmal atrial fibrillation: Main cause of syncope in hypertrophic cardiomyopathy. Arch Mal Coeur Vaiss 1993; 86: 1573-8.
25. Stafford WJ, Trohman RG, Bilsker M, Zaman L, Castellanos A, Myerburg RJ. Cardiac arrest in an adolescent with atrial fibrillation and hypertrophic cardiomyopathy. J Am Coll Cardiol 1986; 7: 701-4.
26. Lopez Gil M, Arribas F, Cosio FG. Ventricular fibrillation induced by rapid atrial rates in patients with hypertrophic cardiomyopathy. Europace 2000; 2: 327-32.
27. Cecchi F, Maron BJ, Epstein SE. Long-term outcome of patients with hypertrophic car-diomyopathy successfully resuscitated after cardiac arrest. J Am Coll Cardiol 1989; 13: 1283-8.
28. Suzuki M, Hirayama T, Marumoto K, Okayama H, Iwata T. Paroxysmal atrial fibrillation as a cause of potentially lethal ventricular arrhythmia with myocardial ischemia in hy-pertrophic cardiomyopathy-a case report. Angiology 1998; 49: 653-7.
29. Dernellis J, Stefanadis C, Toutouzas P. From science to bedside: The clinical role of atrial function. Eur Heart J 2000; 2 (Suppl. K): K48-57.
30. Daubert JC, Pavin D, Gras D et al. Importance of atrial contraction in hypertrophic ob-structive cardiomyopathy: Implications for pacing. J Interv Cardiol 1996; 9: 335-45.
31. Pitsavos C, Aggeli C, Stefanadis C, Toutouzas P. Non-invasive assessment of left atrial performance by echocardiographic modalities, Eur Heart J 2000; 2 (Suppl. K): K26-33.
32. Yu EH, Omran AS, Wigle ED et al. Mitral regurgitation in hypertrophic obstructive car-diomyopathy: Relationship to obstruction and relief with myectomy. J Am Coll Cardiol 2000; 36: 2219-25.
33. Nagueh SF, Lakkis NM, Middleton KJ et al. Changes in left ventricular filling and left atrial function six months after nonsurgical septal reduction therapy for hypertrophic obstructive cardiomyopathy. J Am Coll Cardiol 1999; 34: 1123-8.
34. Matsuda Y, Toma Y, Moritani K et al. Assessment of left atrial function in patients with hypertensive heart disease. Hypertension 1986; 8: 779-85.
35. Bonow RO, Frederick TM, Bacharach SL et al. Atrial systole and left ventricular filling in patients with hypertrophic cardiomyopathy: Effect of verapamil. Am J Cardiol 1983; 51: 1386-91.
36. Sanada H, Shimizu M, Shimizu K et al. Left atrial afterload mismatch in hypertrophic cardiomyopathy. Am J Cardiol 1991; 68: 1049-54.
37. Wagner JA, Sax FL, Weisman HF et al. Calcium-antagonist receptors in the atrial tissue of patients with hypertrophic cardiomyopathy. N Engl J Med 1989; 320: 755-61.
38. Wigle ED, Adelman AG, Auger P, Marquis Y. Mitral regurgitation in muscular subaortic stenosis. Am J Cardiol 1969; 24: 698-706.
39. Kinoshita N, Nimura Y, Okamoto M, Miyatake K, Nagata S, Sakaribara H. Mitral regur-gitation in hypertrophic cardiomyopathy: Noninvasive study by two-dimensional Doppler echocardiography. Br Heart J 1983; 49: 574-83.
40. St. John Sutton MG, Tajik AJ, Gibson DG et al. Echocardiographic assessment of left ventricular filling and septal and posterior wall dynamics in idiopathic hypertrophic subaortic stenosis. Circulation 1978; 57: 512-20.
41. Roberts CS, Roberts WC. Morphologic features. In: Zipes DP, Rowlands DJ, eds. Progress in Cardiology. Philadelphia: Lea & Febiger, 1989: 3-22.
42. Olsen EG. Anatomic and light microscopic characterization of hypertrophic obstructive and non obstructive cardiomyopathy. Eur Heart J 1983; 4 (Suppl. F): 1-8.
43. Maron BJ, Spirito P, Green KJ, Wesley YE, Bonow RO, Arce J. Noninvasive assessment of left ventricular diastolic function by pulsed Doppler echocardiography in patients with hypertrophic cardiomyopathy. J Am Coll Cardiol 1987; 10: 733-42.
44. Hanrath P, Mathey DG, Siegert R, Bleifeld W. Left ventricular relaxation and filling pattern in different forms of left ventricular hypertrophy: An echocardiographic study. Am J Cardiol 1980; 45: 15-23.
45. Spirito P, Maron BJ, Bonow RO. Noninvasive assessment of left ventricular diastolic function: Comparative analysis of Doppler echocardiographic and radionuclide angiographic techniques. J Am Coll Cardiol 1986; 7: 518-26.
46. Losi MA, Betocchi S, Grimaldi M. Heterogeneity of left ventricular filling dynamics in hypertrophic cardiomyopathy. Am J Cardiol 1994; 73: 987-90.
47. Spirito P, Lakatos E, Maron BJ. Degree of left ventricular hypertrophy in patients with hypertrophic cardiomyopathy and chronic atrial fibrillation. Am J Cardiol 1992; 69: 1217-22.
48. Panza JA, Petrone RK, Fananapazir L, Maron BJ. Utility of continuous wave Doppler in noninvasive assessment of the left ventricular outflow tract pressure gradient in patients with hypertrophic cardiomyopathy. J Am Coll Cardiol 1992; 19: 91-9.
49. Cannon RO, Rosing DR, Maron BJ et al. Myocardial ischemia in hypertrophic cardio-myopathy: Contribution of inadequate vasodilator reserve and elevated left ventricular filling pressures. Circulation 1985; 71: 234-43.
50. O'Gara PT, Bonow RO, Maron BJ et al. Myocardial perfusion abnormalities in patients with hypertrophic cardiomyopathy: Assessment with thallium-201 emission computed tomography. Circulation 1987; 76: 1214-23.
51. Maron BJ, Epstein SE, Roberts WC. Hypertrophic cardiomyopathy and transmural myo-cardial infarction without significant atherosclerosis of the extramural coronary arteries. Am J Cardiol 1979; 43: 1086-102.
52. Pasternac A, Noble J, Streulens Y, Elie R, Henschke C, Bourassa MG. Pathophysiology of chest pain in patients with cardiomyopathies and normal coronary arteries. Circulation 1982; 65: 778-89.
53. Camici P, Chiriatti G, Lorenzoni R et al. Coronary vasodilation is impaired in both hyper-trophied and nonhypertrophied myocardium of patients with hypertrophic cardiomyopathy: A study with nitrogen-13 ammonia and positron emission tomography. J Am Coll Cardiol 1991; 17: 879-86.
54. Yamaji K, Fujimoto S, Yutani C et al. Does the progression of myocardial fibrosis lead to atrial fibrillation in patients with hypertrophic cardiomyopathy? Cardiovasc Pathol 2001; 10: 297-303.
55. Prasad K, Frenneaux MP. Sudden death in hypertrophic cardiomyopathy: Potential im-portance of altered autonomic control of vasculature. Heart 1998; 79: 538-40.
56. Frenneaux MP, Counihan PJ, Caforio ALP, Chikamori T, McKenna WJ. Abnormal blood pressure response during exercise in hypertrophic cardiomyopathy. Circulation 1991; 82: 1995-2002.
57. Brignole M, Gianfranchi L, Menozzi C et al. Role of autonomic reflexes in syncope associated with paroxysmal atrial fibrillation. J Am Coll Cardiol 1993; 22: 1123-9.
58. Gruver EJ, Fatkin D, Dodds GA et al. Familial hypertrophic cardiomyopathy and atrial fibrillation caused by Arg663His beta-cardiac myosin heavy chain mutation. Am J Cardiol 1999; 83 (12A): 13H-18H.
59. Varnava A, Baboonian C, Davison F et al. New mutation of the cardiac troponin T gene causing familial hypertrophic cardiomyopathy without left ventricular hypertrophy. Heart 1999; 82: 621A-624A.
60. Richard P, Charron P, Leclercq C et al. Homozygotes for a R869G mutation in the beta-myosin heavy chain gene have a severe form of familial hypertrophic cardiomyopathy. J Mol Cell Cardiol 2000; 32: 1575-83.
61. Fuster V, Ryden LE, Asinger RW et al. ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation: Executive summary a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences. Circulation 2003; 104: 2118-50
62. Falk RH. Atrial fibrillation. N Engl J Med 2001; 344: 1067-78.
63. Benjamin EJ, Wolf PA, DAgostino RB, Silbershatz H, Kannel WB, Levy D. Impact of atrial fibrillation on the risk of death. The Framingham Heart Study. Circulation 1998; 98: 946-52.
64. Middlekauff HR, Stevenson WG, Stevenson LW. Prognostic significance of atrial fibrillation in advanced heart failure. A study of 390 patients. Circulation 1991; 84: 40-8.
65. Cameron A, Schwartz MJ, Kronmal RA, Kosinski AS. Prevalence and significance of atrial fibrillation in coronary artery disease (CASS Registry). Am J Cardiol 1988; 61: 714-7.
66. Dernellis J, Tsiamis E, Stefanadis C et al. Effects of postural changes on left atrial function in patients with hypertrophic cardiomyopathy. Am Heart J 1998; 136: 982-7.
67. Schlepper M. Identification of patients with atrial fibrillation at risk for thromboembolism. In: Olsson SB, Allessie MA, Campbell RWF, eds. Atrial Fibrillation. Mechanisms and Therapeutic Strategies. Armonk (NY): Futura Publishing, 1994: 15-24.
68. Lavy S, Stern S, Melamed E et al. Effect of chronic atrial fibrillation on regional cerebral blood flow. Stroke 1980; 1: 35-8.
69. Longo G, Cecchi F, Grossi A et al. Coagulation and platelet function in hypertrophic car-diomyopathy. Thromb Haemost 1984; 51: 299.
70. Yarom M, Lewis BS, Lijovetsky G et al. Platelet studies in patients with hypertrophic car-diomyopathy. Cardiovasc Res 1982; 16: 324-30.
71. McKenna WJ, Oakley CM, Krikler DM, Goodwin JF. Improved survival with amio- darone in patients with hypertrophic cardiomyopathy and ventricular tachycardia. Br Heart J 1985; 53: 412-16.
72. Cecchi F, Olivotto I, Montereggi A, Squillantini G, Dolara A, Maron BJ. Prognostic value of nonsustained ventricular tachycardia and efficacy of amiodarone treatment in an unselected patient population with hypertrophic cardiomyopathy. Heart 1998; 79: 331-6.
73. Prystowski EN. Management of atrial fibrillation: Therapeutic options and clinical decisions. Am J Cardiol 2000; 85: 3D-11D.
74. Reiffel JA. Drug choices in the treatment of atrial fibrillation. Am J Cardiol 2000; 85: 12D-19D.
75. Tendera M, Wycisk A, Schneeweiss A, Polonski L, Wodniecki J. Effect of sotalol on ar-rhythmias and exercise tolerance in patients with hypertrophic cardiomyopathy. Cardiology 1993; 82: 335-42.
76. Friedman PA, Dijkman B, Warman EN et al. Atrial therapies reduce atrial arrhythmia burden in defibrillator patients. Circulation 2001; 104: 1023-28.
77. Ozcan C, Jahangir A, Friedman PA et al. Long-term survival after ablation of the atrioven-tricular node and implantation of a permanent pacemaker in patients with atrial fibrillation. N Engl J Med 2001; 344: 1043-51.
78. Wyse DG, Waldo AL, DiMarco JP et al. Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) Investigators. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 2002; 347: 1825-33.
79. Saxonhouse SJ, Curtis AB. Risks and benefits of rate control versus maintenance of sinus rhythm. Am J Cardiol 2003; 91 (6A): 27-32.
80. Spirito P, Maron BJ, Bonow RO, Epstein SE. Occurrence and significance of progressive left ventricular wall thinning and relative cavity dilatation in patients with hypertrophic cardiomyopathy. Am J Cardiol 1987; 60: 123-9.